Abstract
Introduction
Mesenchymal stem cells (MSCs) [6, 7] . [9] . Therefore, it is likely that future cell-based therapies will require a tight control of the cell dose to be transplanted in order to achieve a successful and safe outcome. In 
com). Importantly, MSC isolation may require a positive selection coupled to depletion steps. This is due to the complex immunophenotype defining MSCs, which are positive for CD73, CD105, CD146, CD271 among other markers but lack expression of CD34, CD45, CD14, HLA-DR, and CD19. Although most, if not all, such markers are highly modulated in culture, other markers such as STRO-1 [2], SSEA-1/CD15 [3], SSEA-4 [4] or CD146 [5] have been proposed to label an in vivo mesenchymal precursor, though it is not clear yet whether they define a subset of MSCs or the 'master' very immature MSC. In addition to the phenotype, their differentiation capacity using clonal cultures of MSCs has provided much information about the in vitro heterogeneity of this population. While most of the cells within a given MSC population show a uni-or bipotential capacity of differentiation, there are only a small number of cells exhibiting tripotential differentiation capacity (osteogenesis, chondrogenesis and adipogenesis). These data suggest a possible hierarchical model where the tripotent cells can be considered as early mesenchymal progenitors within a heterogeneous cell culture that displays a sequential loss of lineage potential

Successful haematopoietic stem cell (HSC)-based therapies have been carried out for almost 50 years. Infusion of high numbers of HSCs is associated with a rapid haematopoietic recovery and low probability of graft failure [8] although it may be linked to an increased incidence of graft-versus-host-disease (GVHD) in an allogeneic setting
Mechanisms of immunological tolerance
Immunological tolerance is often defined by the failure of the immune system to mount a response against a specific antigen [23, 24] [27, 28] . For developing thymocytes, the molecular mechanism of anergy induction is unclear but may be linked to signalling through the antigen receptor (TCR) in a partial agonist mode [29] [30] [31] [33] or upon recirculation into the thymus of activated T cells [34, 35] or by the activity of veto cells that kill autoreactive cytotoxic T cells [36] . Anergy [42] . At the biochemical level, the induction of T-cell anergy correlates with impairment of early TCRdependent signalling along the ras-dependent signalling [43, 44] [49, 50] 
. This strategy had a beneficial effect on graft survival (when not inducing sensitization of the recipient). The advances in our understanding of the tolerogenic mechanism lead us to consider several possibilities for the immunomodulatory and tolerogenic properties of MSCs
Clinical applications based on MSCs immune modulatory properties: overview of ongoing clinical trials
As described above, MSCs are multi-potent non-haematopoietic progenitor cells capable of differentiating into various mesenchymal lineages, being able to migrate to damaged tissues and favour tissue repair. Biologically, MSCs release cytokines and growth factors supporting the differentiation of the HSCs, which is based on an interaction between MSCs and haematopoietic cells through signalling pathways such as Notch, Tie2 and the axis CXCR4-CXCL12 [71-74]. From an immunological point of view, the inhibition of T-cell responses by MSCs correlates with cyclin D2 inhibition [75] and a p27
kip1 up-regulation [76] . Both contact dependent and independent mechanisms have been involved. [77] . They also reduce the expression of co-stimulatory molecules and down-regulate IL12 secretion in mature antigen presenting cells [78, 79] . [82, 83] . [84] . Le Blanc K et al. [13] [85] . Strikingly, acute GVHD disappeared completely in 75% of patients [85] . These studies have been further extended in Europe with 55 patients enrolled [86] [96] [97] [98] . Although these pre-clinical and clinical trials are still very preliminary, the results are promising and therefore efforts in this cell therapy field should be continued [96] [97] [98] 
They also block the proliferation and differentiation of B lymphocytes, in an extracellular response kinase (ERK) and p38 MAP kinase pathway-dependent manner
The immune-privileged properties attributed to MSCs make them a powerful tool that could be used in many inflammatory
(i) co-transplantation of MSCs along with pancreatic islets for type 1 diabetic patients (Fuzhou General Hospital, China) in order to protect the transplanted islets from inflammatory damage, thus facilitating islet engraftment and (ii) MSCs transplantation in recipients who have undergone a kidney transplant in order to suppress immune rejection and improve donor kidney survival (Fuzhou General Hospital, China). b) Treatment of chronic inflammatory diseases. For instance, MSCs transplantation in decompensate cirrhosis (University of Tehran, Iran) or chronic allograft nephropathy (Fuzhou General Hospital, China). c) Treatment of autoimmune diseases. Immunological properties of MSCs are being currently harnessed in multiple sclerosis clinical trials (University of Cambridge, UK) and in Lupus Nephritis clinical trials (Organ Transplant Institute, China). d) Treatment of diseases of unknown aetiology but with a strong inflammatory response. MSCs are being used in Crohn's disease to decrease inflammation (Osiris Therapeutics) and in the treatment of moderate to severe Chronic Obstructive Pulmonary Disease (Osiris Therapeutics). e) Treatment of GVHD after an allogeneic HSC transplantation (HSCT). Allogeneic HSC transplant is a well-established treatment for several haematopoietic and non-haematopoietic diseases. Recipients receiving an allogeneic HSCT are immunosuppressed in order to prevent rejection of the transfused HSCs. GVHD is induced by T cells either transplanted or generated from infused donor HSCs, which react with donor tissue. Because of their immunoregulatory capacity, ex vivo expanded MSCs are being used in clinical trials to treat severe GVHD [80]. To date, GVHD is probably the more susceptible disease prone to be treated with MSCs. In fact, many multi-centre randomized trials have been started. Preliminary results about the use of MSCs in GVHD are discussed below in detail.
MSC in the HSCT setting
Allogeneic HSCT is a potentially curative treatment option for many patients diagnosed with haematologic malignancies. Its efficacy is based both on the high doses of chemotherapy and radiotherapy administered prior to transplantation and on the immune effect of T lymphocytes from the graft which may recognize and exert a cytotoxic effect against tumour cells from the host inducing a graftversus-leukaemia (GVL) effect. An important clinical observation
Based on their immune modulatory properties, MSCs have been used as a promising approach for the treatment of GVHD
transplanted haploidentical MSCs to a patient with severe treatment-resistant grade IV acute GVHD of the gut and liver. The clinical response was striking with normalization of stool and bilirubin on two separated occasions. Subsequently, the same authors reported their experience on eight patients with steroid refractory grades III-IV acute GVHD and one patient with extensive chronic GVHD treated with MSCs
MSCs as a model to study cell transformation and disease
In agreement with the cancer stem cell theory [99] [110] . Likewise, the presence of MSCs in the tumour stroma could facilitate breast cancer metastasis [111] or the growth of syngeneic tumours [112, 113] [91, 114] or acute lymphoblastic leukaemia [115] . Activation of anti-apoptotic pathways seems to play a central role in this regard since BM-derived MSC are resistant to chemotherapy-induced apoptosis [116] and also contribute to generate drug resistance in tumour cells [115, 117] .
It [123] , Kaposi's sarcoma [124] or hepatoma [125, 126] . Due to the ability of MSCs to migrate and seed tumours, they have also been used as vehicles to deliver oncolytic viruses into tumours and metastasis [127, 128, and [131] . In addition, Wnt signalling also regulates the invasion capacity and the proliferation of human MSC [132, 133] [134] , leading therefore to a malignant transformation [91, 105, 134] .
In 
